Duopharma Seeking To Diversify Manufacturing Domain
Leonard Ariff Abdul Shatar, Group Managing Director, Duopharma Biotech
13-Mar-24 08:00
Embed Podcast
You can share this podcast by copying this HTML to your clipboard and pasting into your blog or web page.
Close
Malaysian pharmaceutical Duopharma Biotech achieved their best financial performance to date in 2022, reaching record highs for revenue and profit. However 2023 was not as kind, with profit after tax falling by 25% despite top line growth. How are they looking to reverse course in 2024? We discuss strategy with Group Managing Director Leonard Ariff Abdul Shatar.
Produced by: Chin Wai Lun
Presented by: Shazana Mokhtar
This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.
Categories: sponsored content, medical advances, managing
Tags: duopharma biotech, pharmaceuticals, market growth,
